

Third Quarter 2025 Results

Merit Medical Investor Call

October 30, 2025

Martha Aronson

President and CEO

Raul Parra

CFO



CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:

- statements preceded or followed by, or that include the words, "may," "will," "should," "expects," "plans," "anticipates," "intends," "seeks," "believes," "estimates," "projects," "forecasts," "potential," "target," "continue," "upcoming," "optimistic" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;
- statements that address Merit's future operating performance or events or developments that Merit's management expects or anticipates will occur, including, without limitation, any statements regarding Merit's projected revenues, earnings or other financial measures, Merit's plans and objectives for future operations, Merit's proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit's Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and
- statements regarding Merit's past performance, efforts, or results about which inferences or assumptions may be made, including statements preceded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

The forward-looking statements contained in this release are based on Merit management's current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and could differ materially, from Merit's expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

The following are some of the important risks and uncertainties that could cause Merit's actual results to differ from management's expectations in any forward-looking statements: risks and uncertainties associated with consequences of Merit's executive succession planning activities and leadership transition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed or prospective tariffs, duties or other measures; risks and uncertainties associated with Merit's proposed acquisition of the C2 CryoBalloon device and related assets from Pentax of America, Inc., the possibility that Merit may not complete the proposed acquisition and, if the acquisition is completed, Merit's integration of the acquired products and Merit's ability to achieve projected financial results, product development and other projected benefits of the proposed acquisition; risks and uncertainties associated with Merit's integration of the Biolife Delaware, L.L.C. ("Biolife") business and operations and its ability to achieve financial results, product development and other anticipated benefits of such acquisition; risks and uncertainties associated with Merit's integration of products acquired from Cook Medical Holdings LLC in November 2024 (the "Cook Transaction") and Merit's ability to achieve anticipated financial results, product development and other anticipated benefits of such acquisition; effects of the Convertible Notes on Merit's net income and earnings per share performance; disruptions in Merit's supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions, including the ongoing "shutdown" of the United States government; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit's potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit's products; the safety, efficacy and patient and physician adoption of Merit's products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit's products; litigation and other judicial proceedings affecting Merit; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Department of Justice; failure to comply with U.S. and foreign laws and regulations; restrictions on Merit's liquidity or business operations resulting from its debt agreements; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit's effective tax rate; termination of relationships with Merit's suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit's existing or future products obsolete; market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties which may affect Merit's business, operations and financial condition, see Part I, Item 1A. "Risk Factors" in Merit's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, which Merit updated in Part II, Item 1A. "Risk Factors" in Merit's Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, which Merit filed with the SEC.

All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this presentation are made only as of the date of this presentation, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.



NON-GAAP FINANCIAL MEASURES

Although Merit's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"), Merit's management believes that certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of Merit's ongoing operations and can be useful for period-over-period comparisons of such operations. Certain financial measures included in this presentation, or which may be referenced in management's discussion of Merit's historical and future operations and financial results, have not been calculated in accordance with GAAP, and, therefore, are referenced as non-GAAP financial measures. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Additionally, non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit's business or results of operations. Please refer to "Notes to Non-GAAP Financial Measures" at the end of these materials for more information.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this presentation are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.



Financial Summary: GAAP

In millions, except per share amounts and percentages

	Q3 2025	Q3 2024	% Change	YTD 2025	YTD 2024	% Change
Revenue	\$384.2	\$339.8	13.0%	\$1,122.0	\$1,001.4	12.0%
Gross Margin	48.5%	46.4%	4.7%	48.4%	47.0%	3.0%
Operating Margin	11.1%	11.0%	1.2%	11.6%	11.9%	(2.2)%
Net Income	\$27.8	\$28.4	(2.4)%	\$90.5	\$92.4	(2.1)%
Earnings per Share	\$0.46	\$0.48	(3.0)%	\$1.49	\$1.57	(4.8)%

Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts.



Financial Summary: Non-GAAP*

In millions, except per share amounts and percentages

	Q3 2025	Q3 2024	% Change	YTD 2025	YTD 2024	% Change
Revenue	\$366.2 [†]	\$339.8	7.8%	\$1,069.7 [†]	\$1,001.4	6.8%
Gross Margin	53.6%	50.9%	5.2%	53.4%	51.1%	4.5%
Operating Margin	19.7%	19.2%	2.6%	20.0%	18.8%	6.9%
Net Income	\$54.9	\$51.2	7.4%	\$168.9	\$149.0	13.3%
Earnings per Share	\$0.92	\$0.86	6.7%	\$2.79	\$2.53	10.2%

Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts.

* See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.

† A non-GAAP financial measure, representing constant currency revenue, organic.



Revenue Breakdown – Q3

In thousands, except percentages

Region	Q3 2025	Q3 2024	\$ Change	% Change	CC % Change*
U.S.	\$230,597	\$206,492	\$24,105	11.7%	12.1%
APAC	64,855	60,382	4,473	7.4%	7.7%
EMEA	71,531	58,474	13,057	22.3%	17.5%
Rest of World	17,174	14,497	2,677	18.5%	17.8%
Total International	153,560	133,353	20,207	15.2%	13.1%
Total	\$384,157	\$339,845	\$44,312	13.0%	12.5%

* A non-GAAP financial measure, representing revenue growth on a constant currency ("CC") basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.



Revenue Breakdown - YTD

In thousands, except percentages

Region	YTD 2025	YTD 2024	\$ Change	% Change	CC % Change*
U.S.	\$671,243	\$587,250	\$83,993	14.3%	14.3%
APAC	193,983	190,053	3,930	2.1%	2.7%
EMEA	207,431	181,802	25,629	14.1%	11.7%
Rest of World	49,313	42,251	7,062	16.7%	22.0%
Total International	450,727	414,106	36,621	8.8%	8.6%
Total	\$1,121,970	\$1,001,356	\$120,614	12.0%	12.0%

* A non-GAAP financial measure, representing revenue growth on a constant currency ("CC") basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.



Financial Metrics

In millions

Metric	Q3 2025	Q3 2024	YTD 2025	YTD 2024
Depreciation & Amortization	\$31.3	\$26.4	\$91.6	\$74.1
Stock Comp (performance-based)	9.0	3.7	19.7	9.4
Stock Comp (not performance-based)	4.6	3.1	13.9	9.6
Operating Cash Flow	75.0	47.3	198.9	152.1
Capital Expenditures-Property and Equipment	22.4	9.4	57.3	31.7



Fiscal Year 2025 Financial Guidance

Revenue and Earnings Guidance*

Financial Measure	Updated Guidance		Prior Guidance ⁽²⁾	
	Year Ending December 31, 2025	% Change Y/Y	Year Ending December 31, 2025	% Change Y/Y
Net Sales	\$1.502 - \$1.515 billion	11% - 12%	\$1.495 - \$1.507 billion	10% - 11%
Cardiovascular Segment	\$1.430 - \$1.441 billion	10% - 11%	\$1.423 - \$1.434 billion	9% - 10%
Endoscopy Segment	\$72.0 - \$74.0 million	32% - 34%	\$72.0 - \$73.0 million	32% - 34%
Non-GAAP				
Earnings Per Share ⁽¹⁾	\$3.66 - \$3.79	6% - 10%	\$3.52 - \$3.72	2% - 8%

(1) Merit's non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 calculated using the if-converted method of approximately \$0.04 per share for the year ending December 31, 2025. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.

(2) "Prior Guidance" reflects Merit's full-year 2025 financial guidance, previously introduced on July 30, 2025.

2025 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*

	Updated Guidance		Prior Guidance ⁽¹⁾	
	Low	High	Low	High
2025 Net Sales Guidance - % Change from Prior Year (GAAP)	10.7%	11.7%	10.2%	11.1%
Estimated impact of foreign currency exchange rate fluctuations	(0.5%)	(0.5%)	(0.5%)	(0.5%)
2025 Net Sales Guidance - % Change from Prior Year (Constant Currency)	10.3%	11.2%	9.7%	10.6%

(1) "Prior Guidance" reflects Merit's full-year 2025 financial guidance, previously introduced on July 30, 2025.

* Percentage figures approximated; percentage and dollar figures may not foot due to rounding

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit's future financial results, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit's financial guidance for the year ending December 31, 2025, is subject to risks and uncertainties identified in this presentation and Merit's filings with the U.S. Securities and Exchange Commission (the "SEC"). This guidance is based on information and estimates available to Merit as of October 30, 2025. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.



Appendix

Notes to Non-GAAP Financial Measures

For additional details, please see the accompanying press release and forward-looking statement disclosure.

These presentation materials and associated commentary from Merit's management, as well as the press release issued today, use non-GAAP financial measures, including:

- constant currency revenue;
- constant currency revenue, organic;
- non-GAAP gross profit and margin;
- non-GAAP operating income and margin;
- non-GAAP net income;
- non-GAAP earnings per share; and
- free cash flow.

Merit's management team uses these non-GAAP financial measures to evaluate Merit's profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit's management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.

Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit's business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit's business or results of operations.



Notes to Non-GAAP Financial Measures (cont.)

Constant Currency Revenue

Merit's constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustments of (\$1.9) million and (\$0.8) million to reported revenue for the three and nine-month periods ended September 30, 2025, respectively, were calculated using the applicable average foreign exchange rates for the three and nine-month periods ended September 30, 2024.

Constant Currency Revenue, Organic

Merit's constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue. With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions. For the three-month period ended September 30, 2025, Merit's constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) Merit's merger transaction with Biolife in May 2025 (the "Biolife Merger") and (ii) the Cook Transaction. For the nine-month period ended September 30, 2025, Merit's constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the Biolife Merger, (ii) the Cook Transaction and (iii) the assets acquired from EndoGastric Solutions, Inc. in July 2024.

Non-GAAP Gross Profit and Margin

Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.

Non-GAAP Operating Income and Margin

Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit's management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.



Notes to Non-GAAP Financial Measures (cont.)

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliations

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit's corresponding financial measures prepared in accordance with GAAP, in each case, for the three and nine-month periods ended September 30, 2025 and 2024. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of \$4.6 million and \$3.1 million for the three-month periods ended September 30, 2025 and 2024, respectively and \$13.9 million and \$9.6 million for the nine-month periods ended September 30, 2025 and 2024, respectively.



Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited; in thousands except per share amounts)

	Three Months Ended September 30, 2025				Three Months Ended September 30, 2024			
	Pre-Tax	Tax Impact	After-Tax	Per Share Impact	Pre-Tax	Tax Impact	After-Tax	Per Share Impact
GAAP net income	\$ 38,540	\$ (10,785)	\$ 27,755	\$ 0.46	\$ 36,657	\$ (8,213)	\$ 28,444	\$ 0.48
<i>Non-GAAP adjustments:</i>								
Cost of Sales								
Amortization of intangibles	19,212	(4,539)	14,673	0.24	14,896	(3,522)	11,374	0.19
Inventory mark-up related to acquisitions	183	(43)	140	0.00	559	(132)	427	0.01
Operating Expenses								
Contingent consideration expense	32	(5)	27	0.00	103	(6)	97	0.00
Amortization of intangibles	2,560	(604)	1,956	0.03	2,038	(482)	1,556	0.03
Performance-based share-based compensation (a)	9,028	(1,413)	7,615	0.13	3,736	(609)	3,127	0.05
Corporate restructuring (b)	286	(67)	219	0.00	2,084	(492)	1,592	0.03
Acquisition-related	(68)	16	(52)	(0.00)	2,351	(555)	1,796	0.03
Medical Device Regulation expenses (c)	1,655	(391)	1,264	0.02	1,983	(468)	1,515	0.03
Other (d)	74	(17)	57	0.00	125	(30)	95	0.00
Other (Income) Expense								
Amortization of long-term debt issuance costs	1,414	(334)	1,080	0.02	1,477	(349)	1,128	0.02
Other non-operating loss (e)	260	(61)	199	0.00	—	—	—	—
Non-GAAP net income	<u>\$ 73,176</u>	<u>\$ (18,243)</u>	<u>\$ 54,933</u>	<u>\$ 0.92</u>	<u>\$ 66,009</u>	<u>\$ (14,858)</u>	<u>\$ 51,151</u>	<u>\$ 0.86</u>
Diluted shares					59,919			59,537

Note: Certain per-share impacts may not sum to totals due to rounding.



Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited; in thousands except per share amounts)

	Nine Months Ended September 30, 2025				Nine Months Ended September 30, 2024			
	Pre-Tax	Tax Impact	After-Tax	Per Share Impact	Pre-Tax	Tax Impact	After-Tax	Per Share Impact
GAAP net income	\$ 119,877	\$ (29,394)	\$ 90,483	\$ 1.49	\$ 116,848	\$ (24,438)	\$ 92,410	\$ 1.57
Non-GAAP adjustments:								
Cost of Sales								
Amortization of intangibles	55,798	(13,184)	42,614	0.70	40,827	(9,654)	31,173	0.53
Inventory mark-up related to acquisitions	250	(59)	191	0.00	559	(132)	427	0.01
Operating Expenses								
Contingent consideration expense	1,198	29	1,227	0.02	292	(31)	261	0.00
Amortization of intangibles	7,497	(1,771)	5,726	0.09	5,546	(1,312)	4,234	0.07
Performance-based share-based compensation (a)	19,681	(2,344)	17,337	0.29	9,396	(1,466)	7,930	0.13
Corporate restructuring (b)	2,873	(678)	2,195	0.04	2,030	(479)	1,551	0.03
Acquisition-related	2,088	(2)	2,086	0.03	3,610	(852)	2,758	0.05
Medical Device Regulation expenses (c)	4,883	(1,153)	3,730	0.06	6,120	(1,445)	4,675	0.08
Other (d)	103	(24)	79	0.00	302	(72)	230	0.00
Other (Income) Expense								
Amortization of long-term debt issuance costs	4,242	(1,002)	3,240	0.05	4,431	(1,046)	3,385	0.06
Other non-operating loss (gain) (e)	11	(61)	(50)	(0.00)	—	—	—	—
Non-GAAP net income	<u>\$ 218,501</u>	<u>\$ (49,643)</u>	<u>\$ 168,858</u>	<u>\$ 2.79</u>	<u>\$ 189,961</u>	<u>\$ (40,927)</u>	<u>\$ 149,034</u>	<u>\$ 2.53</u>
Diluted shares				60,604				58,948

Note: Certain per-share impacts may not sum to totals due to rounding.



Reconciliation of GAAP Operating Income to Non-GAAP Operating Income (Unaudited; in thousands except percentages)

	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024		Nine Months Ended September 30, 2025		Nine Months Ended September 30, 2024	
	Amounts	% Sales	Amounts	% Sales	Amounts	% Sales	Amounts	% Sales
Net Sales as Reported	\$ 384,157		\$ 339,845		\$ 1,121,970		\$ 1,001,356	
GAAP Operating Income	42,612	11.1 %	37,261	11.0 %	130,525	11.6 %	119,129	11.9 %
Cost of Sales								
Amortization of intangibles	19,212	5.0 %	14,896	4.4 %	55,798	5.0 %	40,827	4.1 %
Inventory mark-up related to acquisitions	183	0.0 %	559	0.2 %	250	0.0 %	559	0.1 %
Operating Expenses								
Contingent consideration expense	32	0.0 %	103	0.0 %	1,198	0.1 %	292	0.0 %
Amortization of intangibles	2,560	0.7 %	2,038	0.6 %	7,497	0.7 %	5,546	0.6 %
Performance-based share-based compensation (a)	9,028	2.4 %	3,736	1.1 %	19,681	1.8 %	9,396	0.9 %
Corporate restructuring (b)	286	0.1 %	2,084	0.6 %	2,873	0.3 %	2,030	0.2 %
Acquisition-related	(68)	(0.0) %	2,351	0.7 %	2,088	0.2 %	3,610	0.4 %
Medical Device Regulation expenses (c)	1,655	0.4 %	1,983	0.6 %	4,883	0.4 %	6,120	0.6 %
Other (d)	74	0.0 %	125	0.0 %	103	0.0 %	302	0.0 %
Non-GAAP Operating Income	\$ 75,574	19.7 %	\$ 65,136	19.2 %	\$ 224,896	20.0 %	\$ 187,811	18.8 %

Note: Certain percentages may not sum to totals due to rounding.



Footnotes to Reconciliations of GAAP Net Income to Non-GAAP Net Income and GAAP Operating Income to Non-GAAP Operating Income

- a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.
- b) Includes employee termination benefits associated with activities related to corporate restructuring initiatives and costs to terminate certain distribution contracts from our Biolife Merger.
- c) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation.
- d) Represents costs to comply with Merit's corporate integrity agreement with the the U.S. Department of Justice.
- e) Includes gains and losses associated with the disposal of business units and equity method investment loss (income) from equity investees.



Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP) (Unaudited; in thousands except percentages)

	Three Months Ended September 30,				Nine Months Ended September 30,			
	% Change	2025	2024	% Change	2025	2024		
Reported Revenue	13.0 %	\$ 384,157	\$ 339,845	12.0 %	\$ 1,121,970	\$ 1,001,356		
<i>Add: Impact of foreign exchange</i>		(1,926)	—		(778)	—		
Constant Currency Revenue (a)	12.5 %	\$ <u>382,231</u>	\$ <u>339,845</u>	12.0 %	\$ <u>1,121,192</u>	\$ <u>1,001,356</u>		
<i>Less: Revenue from certain acquisitions</i>		(16,031)	—		(51,445)	—		
Constant Currency Revenue, Organic (a)	7.8 %	\$ <u>366,200</u>	\$ <u>339,845</u>	6.8 %	\$ <u>1,069,747</u>	\$ <u>1,001,356</u>		

(a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this presentation entitled "Notes to Non-GAAP Financial Measures."



Reconciliation of Reported Gross Margin to Non-GAAP Gross Margin (Unaudited; as a percentage of reported revenue)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Reported Gross Margin	48.5 %	46.4 %	48.4 %	47.0 %
<i>Add back impact of:</i>				
Amortization of intangibles	5.0 %	4.4 %	5.0 %	4.1 %
Inventory mark-up related to acquisitions	0.0 %	0.2 %	0.0 %	0.1 %
Non-GAAP Gross Margin	53.6 %	50.9 %	53.4 %	51.1 %

Note: Certain percentages may not sum to totals due to rounding.





MERIT MEDICA®